{"database": "lobbying", "table": "lobbying_filings_raw", "rows": [["c8ad5ca1-e0a7-48b8-bd71-88a2b5e9ca82", "Q3", 7268, "BROYDRICK & ASSOCIATES", 110506, "TONIX PHARMACEUTICALS", 2017, "third_quarter", "2017-10-15T16:07:27.727000-04:00", 40000.0, 0, 0, 0, "{\"url\": \"https://lda.senate.gov/api/v1/filings/c8ad5ca1-e0a7-48b8-bd71-88a2b5e9ca82/\", \"filing_uuid\": \"c8ad5ca1-e0a7-48b8-bd71-88a2b5e9ca82\", \"filing_type\": \"Q3\", \"filing_type_display\": \"3rd Quarter - Report\", \"filing_year\": 2017, \"filing_period\": \"third_quarter\", \"filing_period_display\": \"3rd Quarter (July 1 - Sep 30)\", \"filing_document_url\": \"https://lda.senate.gov/filings/public/filing/c8ad5ca1-e0a7-48b8-bd71-88a2b5e9ca82/print/\", \"filing_document_content_type\": \"text/html\", \"income\": \"40000.00\", \"expenses\": null, \"expenses_method\": null, \"expenses_method_display\": null, \"posted_by_name\": \"Cynthia Broydrick\", \"dt_posted\": \"2017-10-15T16:07:27.727000-04:00\", \"termination_date\": null, \"registrant_country\": \"United States of America\", \"registrant_ppb_country\": null, \"registrant_address_1\": \"1150 Connecticut Ave. NW #615\", \"registrant_address_2\": null, \"registrant_different_address\": false, \"registrant_city\": \"Washington\", \"registrant_state\": \"DC\", \"registrant_zip\": \"20036\", \"registrant\": {\"id\": 7268, \"url\": \"https://lda.senate.gov/api/v1/registrants/7268/\", \"house_registrant_id\": 32405, \"name\": \"BROYDRICK & ASSOCIATES\", \"description\": \"Government relations and lobbying.\", \"address_1\": \"101 Constitution Avenue NW\", \"address_2\": \"Suite 825 East\", \"address_3\": null, \"address_4\": null, \"city\": \"Washington\", \"state\": \"DC\", \"state_display\": \"District of Columbia\", \"zip\": \"20001\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"contact_name\": \"CYNTHIA BROYDRICK\", \"contact_telephone\": \"+1 202-637-0637\", \"dt_updated\": \"2026-01-28T18:44:44.787248-05:00\"}, \"client\": {\"id\": 110506, \"url\": \"https://lda.senate.gov/api/v1/clients/110506/\", \"client_id\": 2486, \"name\": \"TONIX PHARMACEUTICALS\", \"general_description\": \"Pharmaceutical development and manufacturing.\", \"client_government_entity\": false, \"client_self_select\": null, \"state\": \"NY\", \"state_display\": \"New York\", \"country\": \"US\", \"country_display\": \"United States of America\", \"ppb_state\": \"NY\", \"ppb_state_display\": \"New York\", \"ppb_country\": \"US\", \"ppb_country_display\": \"United States of America\", \"effective_date\": \"2017-01-01\"}, \"lobbying_activities\": [{\"general_issue_code\": \"PHA\", \"general_issue_code_display\": \"Pharmacy\", \"description\": \"Funding for a new drug for PTSD.\", \"foreign_entity_issues\": \"\", \"lobbyists\": [{\"lobbyist\": {\"id\": 39821, \"prefix\": null, \"prefix_display\": null, \"first_name\": \"WILLIAM\", \"nickname\": null, \"middle_name\": \"B\", \"last_name\": \"BROYDRICK\", \"suffix\": null, \"suffix_display\": null}, \"covered_position\": null, \"new\": false}], \"government_entities\": [{\"id\": 25, \"name\": \"Defense, Dept of (DOD)\"}, {\"id\": 2, \"name\": \"HOUSE OF REPRESENTATIVES\"}, {\"id\": 1, \"name\": \"SENATE\"}]}], \"conviction_disclosures\": [], \"foreign_entities\": [], \"affiliated_organizations\": []}"]], "columns": ["filing_uuid", "filing_type", "registrant_id", "registrant_name", "client_id", "client_name", "filing_year", "filing_period", "received_date", "amount_reported", "is_amendment", "is_no_activity", "is_termination", "raw_json"], "primary_keys": ["filing_uuid"], "primary_key_values": ["c8ad5ca1-e0a7-48b8-bd71-88a2b5e9ca82"], "units": {}, "query_ms": 4.98429499566555, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}